The Markers and Paracetamol Poisoning Study 2
Launched by NHS LOTHIAN · Apr 5, 2018
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Paracetamol overdose is one of the most common medical emergencies. Annually in the UK, 100,000 people seek medical attention and 50,000 need hospital admission. Treatment is with the antidote acetylcysteine (NAC), which is effective but takes 21 hours to administer intravenously and frequently produces adverse reactions. Paracetamol is the commonest cause of acute liver failure and directly kills around 200 people/year in the UK. Management of paracetamol overdose is estimated to cost around £48 million/year to the NHS.
Current tools that are used to decide who needs treatment are inadequ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 16 years and over.
- • 2. Hospital attendance with paracetamol overdose alone or as part of a mixed overdose
- • 3. Patient is able to give informed consent
- Exclusion Criteria:
- • 1. Patient detained under the Mental Health Act
- • 2. Inability to provide informed consent
- • 3. Unreliable history of overdose
- • 4. Prisoners
About Nhs Lothian
NHS Lothian is a prominent healthcare organization based in Scotland, dedicated to delivering high-quality patient care and advancing medical research. As a key sponsor of clinical trials, NHS Lothian focuses on fostering innovative research initiatives that aim to improve health outcomes and inform clinical practice. With a commitment to ethical standards and patient safety, the organization collaborates with a network of healthcare professionals, academic institutions, and research partners to facilitate robust clinical studies across various therapeutic areas. Through its efforts, NHS Lothian plays a vital role in enhancing the evidence base for healthcare interventions and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, , United Kingdom
Patients applied
Trial Officials
James Dear
Principal Investigator
University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials